Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biofrontera (BFRI) Revenue (2020 - 2025)

Biofrontera has reported Revenue over the past 6 years, most recently at $17.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 36.16% year-over-year to $17.1 million; the TTM value through Dec 2025 reached $41.7 million, up 11.75%, while the annual FY2025 figure was $41.7 million, 11.75% up from the prior year.
  • Revenue for Q4 2025 was $17.1 million at Biofrontera, up from $7.0 million in the prior quarter.
  • Over five years, Revenue peaked at $17.1 million in Q4 2025 and troughed at $4.3 million in Q3 2022.
  • A 5-year average of $8.3 million and a median of $8.7 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: fell 23.88% in 2022 and later skyrocketed 105.83% in 2023.
  • Year by year, Revenue stood at $9.2 million in 2021, then grew by 10.65% to $10.1 million in 2022, then grew by 4.46% to $10.6 million in 2023, then increased by 18.53% to $12.6 million in 2024, then soared by 36.16% to $17.1 million in 2025.
  • Business Quant data shows Revenue for BFRI at $17.1 million in Q4 2025, $7.0 million in Q3 2025, and $9.0 million in Q2 2025.